MM: CAR T-Cell Therapy vs Bispecific T-Cell Engagers
Experts on multiple myeloma discuss the mechanism of action and adverse events for teclistamab and compare CAR T-cell therapy with bispecific T-cell engagers (BiTEs).
Pharmacy Expert Details Causes of Carboplatin/Cisplatin Shortage in the U.S.
Results of a survey from the National Comprehensive Cancer Network indicate that almost all responding institutions are impacted by the carboplatin shortage.
The Future of the NDMM: Comparing Emergent Regimens and Understanding Unmet Needs
Dr. Costa and Dr. Schmidt consider promising emergent treatment options and current unmet needs in the NDMM treatment landscape.
Optimizing Consolidation and Maintenance Therapy in the NDMM Treatment Landscape
Experienced clinicians share their perspectives on maintenance therapy for patients with NDMM.
TRiMM-2: Talquetamab + Daratumumab in Relapsed/Refractory Multiple Myeloma
In the context of other clinical trials for patients with relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, review data from TRiMM-2.
Key Takeaways From RedirecTT-1: Teclistamab + Talquetamab in Relapsed/Refractory MM
Expert perspectives on the real-world use of combination teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Menin Inhibitors in the Second-Line Treatment of AML
The expert panel discuss emerging data on menin inhibitors in the second-line treatment of AML, including an overview of the KOMET-001 trial evaluating ziftomenib.
Exploring Potential Combination Treatments for AML
Experts on acute myeloid leukemia share clinical insights on first-line combination therapies, including the potential role of menin inhibitors in this setting.
Lenvatinib Combo Yields Benefit Regardless of IMDC Risk in Advanced RCC
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
Understanding the Role of Allogeneic Transplants in Patient Care
Discussion centered around the role of allogeneic transplants in the treatment of MDS, MPN, and AML, focusing on the transplant process, eligibility criteria, patient selection, and post-transplant monitoring.
Breakthroughs in AML: Investigational Therapies and Emerging Targets
Subject-matter experts highlight unmet needs in AML treatment, investigational therapies, and emerging targets showcased in recent studies.
Role of Chemoradiation in Node-Positive Bladder Cancer
Key opinion leaders in bladder cancer consider the evolving role of chemoradiation in patients with node-positive disease.
Systemic Therapy for Cisplatin-Ineligible Patients With Bladder Cancer
Expert perspectives on first-line treatment options available to patients with advanced bladder cancer who are ineligible for cisplatin-based chemotherapy.
Non-BCMA Targeting Bispecifics in MM and Future Directions in Care
Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
New Trial Data Informing Optimal Care of Frail Patients with NDMM
Ajay Nooka, MD, MPH, FACP leads a survey of the MAIA study, including a sub-group analysis of the MAIA study in frail patients, as well as findings from the MagnetisMM-6 study.
Patient Case Introduction: A 76-year-old Female Diagnosed with Transplant-ineligible NDMM
Jonathan Kaufman, MD describes a second patient case featuring a 76-year-old female diagnosed with transplant-ineligible NDMM.
Lenvatinib/Pembrolizumab is a ‘Powerful Regimen’ in Advanced RCC
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC
Following their review of data behind amivantamab and mobocertinib in EGFR Exon20+ non–small cell lung cancer, expert oncologists consider factors that help to inform treatment selection.
EGFR Exon20+ NSCLC: Trial Data With Mobocertinib
Joshua Sabari, MD, and Misako Nagasaka, MD, reflect on clinical trial data and experience with mobocertinib in patients with EGFR Exon20+ non–small cell lung cancer.
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites
A Q&A session with the expert panel.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "New Trial Data Informing Optimal Care of Frail Patients with NDMM")
